Last reviewed · How we verify
immunotherapy with Nivolumab
Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.
Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells. Used for Metastatic non-small cell lung cancer, Metastatic melanoma, Renal cell carcinoma.
At a glance
| Generic name | immunotherapy with Nivolumab |
|---|---|
| Sponsor | Taipei Medical University WanFang Hospital |
| Drug class | PD-1 inhibitor |
| Target | PD-1 (Programmed Death-1) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Nivolumab is a monoclonal antibody that binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with its ligands (PD-L1 and PD-L2) expressed on tumor cells and immune cells. This blockade releases the 'brakes' on the immune system, restoring T-cell activation, proliferation, and anti-tumor function. By reinvigorating exhausted T cells, nivolumab enables the immune system to mount an effective response against cancer.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic melanoma
- Renal cell carcinoma
- Classical Hodgkin lymphoma
- Squamous cell carcinoma of the head and neck
- Colorectal cancer (microsatellite instability-high or mismatch repair deficient)
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Rash
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Immune-mediated colitis
- Hypothyroidism
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study (PHASE2)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer (PHASE1, PHASE2)
- A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- immunotherapy with Nivolumab CI brief — competitive landscape report
- immunotherapy with Nivolumab updates RSS · CI watch RSS
- Taipei Medical University WanFang Hospital portfolio CI